Primary Central Nervous System Non-Hodgkin Lymphoma

Primary Central Nervous System Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

20 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4
Recruiting: 1
Ph III recruiting: 1
Growth YoY: —
Industry share: 25%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01973062	Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma	terminated	Phase 2	1	Case Comprehensive Cancer CenterOTHER	1	Jul 24, 2020	clinicaltrials

Data updated 23 days agoSource updated Jul 24, 2020source: clinicaltrials